Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the 2016 Conference on Retroviruses and Opportunistic Infection. This chart details study design and enrollment, gives overall results and breaks results down by age.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!